The Fly

AbbVie recent weakness a buying opportunity, says JPMorgan

JPMorgan analyst Chris Schott views the recent weakness in shares of AbbVie as a buying opportunity ahead of the company’s 2023 guidance on February 9. The analyst sees a "clear path to multiple expansion" as the story shifts from trough earnings to "top tier growth prospects" in 2025 and beyond with little loss of exclusivity exposure. And with the recent selloff following its weak oncology guidance, JPMorgan sees an increasingly attractive setup for AbbVie from here. It keeps an Overweight rating on the shares with a $190 price target.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on ABBV:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More